Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…
MaaT Pharmajanvier 31, 2020
Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational…
MaaT Pharmaseptembre 10, 2019
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…
MaaT Pharmajuin 24, 2019
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…
MaaT Pharmajuin 24, 2019
Nous avons pris note de l’alerte lancée par la FDA (USA) concernant le décès d'un…
MaaT Pharmajuin 14, 2019
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…
MaaT Pharmajuin 4, 2019
“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…
MaaT Pharmamai 21, 2019
- First patents to cover the fundamental processes for accessing the human gut microbiome as…
MaaT Pharmamai 21, 2019
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute…
MaaT Pharmaavril 9, 2019
